Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Prices $2.7M Securities Offering

NEW YORK (GenomeWeb) – Rosetta Genomics said today that it has priced a public offering of 1.9 million securities units at $1.40 each for gross proceeds of roughly $2.7 million.

The units consist of one ordinary share and a warrant to purchase half an ordinary share. The warrants to purchase an aggregate of 974,987 ordinary shares have an exercise price of $1.50 per ordinary share. The warrants will become exercisable immediately upon issuance and expire in five years.

Rosetta said it would use the proceeds of the offering, which is expected to close on or about August 9, for its operations and for other general corporate purposes, which include repayment or refinancing of indebtedness or other corporate borrowings, working capital, intellectual property protection and enforcement, capital expenditures, investments, acquisitions or collaborations, research and development, and product development.

During morning trading on the Nasdaq, shares of Rosetta were down 10 percent at $1.46.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.